Other News

Q3D: Are your established products in compliance?

Here are ELC Group, we pride ourselves of providing our clients with the latest regulatory intelligence and tools for managing an ever-evolving regulatory landscape. One such example is compliance with the ICH guideline Q3D elemental impurities. The guideline was adopted by the CHMP in December 2014 and has come into effect for all new applications on June 2016. All existing approved authorisations must be in compliance by December 2017.

The Q3D guideline is intended "to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients. Elemental impurities can be introduced – either intentionally or unintentionally – by excipients, manufacturing equipment, packaging (primary and secondary) and, of course, the drug substance itself. The ICH Q3D guideline identifies three key components to risk assess elemental impurities:

  1. Evaluation of toxicity data for potential elemental impurities.
  2. Establishment of Permitted Daily Exposure (PDE) values for each element.
  3. Development of controls for limiting inclusion of elemental impurities.

ICH notes that in some cases, a trade-off may be required, such as when manufacturing a product is impossible without introducing metal impurities, but such levels should still be noted.  The remainder of the guideline gets into the specifics of these impurities, including how to test for limits and which metals are known to be toxic to human health. The guideline breaks the various elemental impurities into four different classifications:

Class 1: (As, Cd, Hg and Pb): Highly toxic across all administration routes. These require special consideration during the risk assessment, due to their high toxicity and the potential for them to be present in finished dosage form through contributions of naturally derived materials.

Class 2: Toxic to a greater or lesser extent based on route of administration.

Class 3: Relatively low toxicity by oral route of administration, but require consideration in the risk assessment for other routes of administration.

Class 4: Elemental impurities that have been evaluated but for which a PDE has not been established due to their low inherent toxicity and/or regional regulations.

The guideline can be boiled down to four simple steps:

1. Identify:
Identify the sources of elemental impurities that are known or suspected, or have the potential to end up in the finished product.

2. Analyse:
Determine the probability of occurrence of the elemental impurities in the finished dosage form.

3. Evaluate:
Assess the actual or predicted levels of elemental impurities with the established PDEs.

4. Control:
Develop, document and implement a plan to limit the elemental impurities in the finished dosage form.

At ELC Group we can assist your company and deliver expert services in the following areas:

Determine the impact

In-depth assessment of your products and what levels of elemental impurities they contain, by considering all the potential sources of elemental impurities including:

  • Contributions from elemental impurities that are intentionally added to reactions or processes leading up to the preparation of the drug substance, reagents, starting materials or excipients (e.g. metal catalysts)
  • Those that are known or suspected to be present in the drug substance, reagents, water, starting materials or excipients used in the preparation of the drug product (e.g. lead present in a mined excipient)
  • Those that are known or suspected of being introduced into the drug substance or drug product from manufacturing equipment
  • Those that are known or suspected of being leached into the drug substance and drug product from container closure systems

Compliant documentation

Generate the required documentation to be kept on site and also any subsequent variations that need filing.

Proactive guidance

Follow up with regulatory submissions and discussions with authorities on compliance and specific guidance where needed.

Please let us know any comments you have on this article:

Also see our

press coverage

News Index

11 Feb 2019

Garth Hedenskog joins ELC Group to expand global sales

26 Nov 2018

Industry plans for disruption amid Brexit uncertainty

25 Oct 2018

ELC Group at 5th Nordic Pharmacovigilance Day - Oct 24th, Copenhagen

05 Oct 2018

EU/US MRA - Brief overview and update

21 Aug 2018

Brexit - has the music stopped?

13 Jul 2018

Recent EMA Brexit Survey

15 Jun 2018

The EMA: 100 not out

08 May 2018

MHRA sets its post-Brexit strategic direction

12 Apr 2018

Brexit - Stick or Twist?

20 Mar 2018

Clinical Trials: all change 2019

22 Jan 2018

Orphan Medicines: almost 20 years on

15 Dec 2017

Update on Brexit developments

05 Oct 2017

How recent moves by the FDA spell good news for generics in the US

11 Sep 2017

Medicines for the Elderly – is your drug development strategy up to the mark?

14 Aug 2017

The MNAT initiative – what’s new?

19 Jul 2017

ICH Q12: Light at the end of the tunnel…?

05 Jun 2017

Q3D: Are your established products in compliance?

02 Jun 2017

Key pharmacovigilance trends to watch

08 May 2017

EMA updates guidance on PSURs

10 Apr 2017

New EMA Consultation on the Quality of Inhaled Pharmaceutical Products

16 Mar 2017

European Parliament’s adoption of ‘Options for improving access to medicines’ procedure

16 Feb 2017

Article 58: a hidden potential

24 Jan 2017

Global lifesciences partner ELC Group teams with PSR Group for advanced drug development

19 Jan 2017

A positive step forward for Biosimilar registration

20 Dec 2016

Falsified Medicines Directive – Are you making the right preparations?

21 Nov 2016

New Public consultation launched by the European Commission (EC)

19 Oct 2016

Transatlantic collaboration to boost research and development of medicines for rare diseases

03 Jun 2016

ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona

16 Jun 2015

ELC Group in early-stage development of novel influenza vaccine

09 Jun 2015

ELC Group expands into pharmaceutical product development market

21 Apr 2015

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

24 Feb 2015

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

02 Feb 2015

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference

15 Sep 2014

Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline

20 Aug 2014

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

28 Jul 2014

ELC Group Appoints Head of Regulatory Affairs for Russia and CIS

14 Apr 2014

Global regulatory affairs specialist ELC Group appoints Localization Business Development Manager for new US Office

10 Oct 2013

Global regulatory affairs specialist ELC Group accelerates international expansion plans following 25% revenue growth in 2013

17 Sep 2013

Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor

23 Apr 2013

Global regulatory affairs specialist ELC Group receives accreditation to provide readability testing in Romania

27 Feb 2013

Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia

20 Feb 2013

Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services

10 Jan 2013

Global pharmaceutical regulatory affairs specialist ELC Group hosts International Training Seminar in Mumbai, India

31 Dec 2012

2012 Events

07 Nov 2012

Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore

22 Aug 2012

Global pharmaceutical regulatory affairs specialist ELC Group increases operational support in Ahmedabad

12 Jun 2012

XEVMPD software provider Pharma eReport launches Excel Data Import Service

06 Jun 2012

ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe

28 Mar 2012

ELC Group joins DIA EuroMeeting in Copenhagen

21 Mar 2012

EVMPD software provider Pharma eReport announces full general availability of Centrality XEVMPD compliance solution

08 Mar 2012

ELC Group Hosts Successful International Regulatory Seminar

06 Mar 2012

Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai

23 Feb 2012

Regulatory challenges for 2012 and their impact on marketing authorisation

21 Feb 2012

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

08 Feb 2012

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

07 Dec 2011

Past president of TOPRA and ELC GROUP Advisor speaks at International Regulatory Seminar in Ahmedabad 23 February 2012

27 Sep 2011

ELC GROUP Advisory Board’s Dr. Paolo Biffignandi to write opinion column for industry leading publication

12 Jul 2011

ELC Group aim to foster strategic and economic ties within India and China

25 May 2011

ELC Group announces doubled revenues

11 May 2011

ELC Group appoints former TOPRA President